Proteomics and drug discovery in cancer

Author(s)

Dias, Matheus H. ^[1] ; Kitano, Eduardo S. ^[1] ; Zelanis, Andre ^[2] ; Iwai, Leo K. ^[1]

Affiliation

^[1] Inst Butantan, Ctr Toxins Immune Response & Cell Signaling CeTIC, LETA, Sao Paulo - Brazil

^[2] Univ Fed Sao Paulo ICT UNIFESP, Inst Ciencia & Tecnol, Lab Proteom Func, Sao Paulo - Brazil

• Document type: Review article
• Source: DRUG DISCOVERY TODAY; v. 21, n. 2, p. 264-277, FEB 2016.
• Web of Science Citations: 12

Abstract

Proteomics has emerged as an invaluable tool in the quest to unravel the biochemical changes that give rise to the hallmarks of cancer. In this review, we present the advances and challenges facing proteomics technology as applied to cancer research, and address how the information gathered so far has helped to enhance understanding of the mechanisms underlying the disease and contributed to the discovery of biomarkers and new drug targets. We conclude by presenting a perspective on how proteomics could be applied in the future to determine prognostic biomarkers and direct strategies for effective cancer treatment. (AU)

• FAPESP's process: 12/20186-9 - Molecular mechanisms of functional interaction between Ras and cyclin D1 in Ras-driven malignant cells
• Grantee: Matheus Henrique dos Santos Dias
• Support Opportunities: Scholarships in Brazil - Post-Doctoral
• FAPESP's process: 11/11308-0 - Proteomic analysis of leaves of sugarcane cultivars and genotypes
• Grantee: Eduardo Shigueo Kitano
• Support Opportunities: Scholarships in Brazil - Doctorate (Direct)
• FAPESP's process: 14/06579-3 - System-wide analysis of N-terminal processing and protein diversity in the secretome of tumor cells
• Grantee: André Zelanis Palitot Pereira
• Support Opportunities: Research Grants - Young Investigators Grants
• FAPESP's process: 13/07467-1 - CeTICS - Center of Toxins, Immune-Response and Cell Signaling
• Grantee: Hugo Aguirre Armelin
• Support Opportunities: Research Grants - Research, Innovation and Dissemination Centers - RIDC